Investigation Launched into Capricor Therapeutics Over Potential Securities Fraud Claims

Investor Alert: Pomerantz Law Firm Investigates Capricor Therapeutics

In a significant development for investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR), the Pomerantz Law Firm has announced an investigation into potential claims related to securities fraud and unlawful business practices. This investigation raises concerns regarding whether Capricor’s executives may have engaged in misleading practices that impacted shareholder value, following troubling news regarding the company’s drug approval process.

On May 5, 2025, Capricor released a press statement disclosing updates on its Biologics License Application (BLA) concerning deramiocel, a cell therapy treatment intended for patients suffering from Duchenne Muscular Dystrophy (DMD) cardiomyopathy. During a critical mid-cycle review meeting with the U.S. Food and Drug Administration (FDA), Capricor reported that the FDA confirmed plans for an advisory committee meeting related to the BLA. This news was pivotal, yet it led to a steep decline in the company’s stock price by $3.00, representing a dramatic drop of 29.13% to close at $7.30 per share on May 6, 2025. The steep decline prompted shareholders to seek legal advice, leading to the current investigation by Pomerantz LLP.

Pomerantz LLP, a distinguished law firm with a history spanning over 85 years, specializes in corporate securities class litigation. Founded by Abraham L. Pomerantz, a noted figure in the field of class action law, the firm advocates fiercely for the rights of investors subjected to securities fraud. With offices located in major cities including New York, Chicago, and Los Angeles, Pomerantz has secured significant awards for affected class members, highlighting its commitment to justice.

Danielle Peyton, an attorney at Pomerantz, is leading the investigation and urges any investors who may have suffered losses to discuss their experiences. Interested investors can contact her at [email protected] or by calling 646-581-9980, ext. 7980.

The question at hand is whether Capricor’s leadership acted in the best interest of its investors or whether their actions constituted a breach of fiduciary duty prior to the recent stock market turbulence. The firm’s investigation could have far-reaching implications, potentially leading to a class action lawsuit if sufficient grounds are found. Investors are encouraged to stay informed as developments unfold and to consider their rights moving forward.

In a business environment fraught with risk, the case against Capricor Therapeutics acts as a stark reminder of the vulnerabilities inherent in investing, particularly in the biotech sector where news related to regulatory approvals can have immediate and profound effects on stock prices.

For ongoing updates regarding the investigation and other pertinent information, stakeholders are advised to monitor communications from Pomerantz LLP and to remain vigilant regarding their investments in Capricor. The outcome of this investigation may serve as a vital indicator of Capricor's governance and ethical practices moving forward, making it essential for investors to remain engaged with the firm’s announcements and market activities.

As this story continues to develop, it is crucial for investors in Capricor and those interested in securities law to pay close attention, as the implications of this investigation could echo throughout the biotech investment community. The Pomerantz firm’s involvement illustrates the significant legal resources available for investors seeking justice when corporate misconduct is suspected.